LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.

We previously identified LDOC1 as one of the most significantly differentially expressed genes in untreated chronic lymphocytic leukemia (CLL) patients with respect to the somatic mutation status of the immunoglobulin heavy-chain variable region genes. However, little is known about the normal function of LDOC1, its contribution to the pathophysiology of CLL, or its prognostic significance. In this study, we have investigated LDOC1 mRNA expression in a large cohort of untreated CLL patients, as well as in normal peripheral blood B-cell (NBC) subsets and primary B-cell lymphoma samples. We have confirmed that LDOC1 is dramatically down-regulated in mutated CLL cases compared with unmutated cases, and have identified a new splice variant, LDOC1S. We show that LDOC1 is expressed in NBC subsets (naive > memory), suggesting that it may play a role in normal B-cell development. It is also expressed in primary B-cell lymphoma samples, in which its expression is associated with somatic mutation status. In CLL, we show that high levels of LDOC1 correlate with biomarkers of poor prognosis, including cytogenetic markers, unmutated somatic mutation status, and ZAP70 expression. Finally, we demonstrate that LDOC1 mRNA expression is an excellent predictor of overall survival in untreated CLL patients.

[1]  K. Coombes,et al.  Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression , 2010, Modern Pathology.

[2]  H. Döhner,et al.  Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.

[3]  K. Coombes,et al.  Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. , 2007, The Journal of molecular diagnostics : JMD.

[4]  Sampsa Hautaniemi,et al.  Transcriptional profiling reflects shared and unique characters for CD34+ and CD133+ cells. , 2006, Stem cells and development.

[5]  Je‐ho Lee,et al.  Alternative splicing variants of IRF-1 lacking exons 7, 8, and 9 in cervical cancer. , 2006, Biochemical and biophysical research communications.

[6]  E. Giné,et al.  ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia , 2006, Clinical Cancer Research.

[7]  H. Döhner,et al.  Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. , 2005, Blood.

[8]  T. Takenawa,et al.  WAVE3 functions as a negative regulator of LDOC1. , 2005, Journal of biochemistry.

[9]  A. Iavarone,et al.  Id family of helix-loop-helix proteins in cancer , 2005, Nature Reviews Cancer.

[10]  M. Fukuzawa,et al.  LDOC1, a novel MZF‐1‐interacting protein, induces apoptosis , 2005, FEBS letters.

[11]  D. Oscier,et al.  ZAP-70 in B cell malignancies , 2005, Leukemia & lymphoma.

[12]  Ida Retter,et al.  VBASE2, an integrative V gene database , 2004, Nucleic Acids Res..

[13]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[14]  R. Abseher,et al.  Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[16]  G. Rassidakis,et al.  Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma , 2004, Modern Pathology.

[17]  Adrian Wiestner,et al.  ZAP-70 expression and prognosis in chronic lymphocytic leukaemia , 2004, The Lancet.

[18]  F. Rösel,et al.  Leucine‐zipper protein, LDOC1, inhibits NF‐κB activation and sensitizes pancreatic cancer cells to apoptosis , 2003, International journal of cancer.

[19]  David R. Anderson,et al.  Model selection and multimodel inference : a practical information-theoretic approach , 2003 .

[20]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[21]  Kevin R Coombes,et al.  High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. , 2003, Blood.

[22]  G. Juliusson,et al.  Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. , 2003, Blood.

[23]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[24]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[25]  T. Imamura,et al.  High frequency of Ikaros isoform 6 expression in acute myelomonocytic and monocytic leukemias: implications for up-regulation of the antiapoptotic protein Bcl-XL in leukemogenesis. , 2002, Blood.

[26]  David Botstein,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[27]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[28]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[29]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[30]  K Nagasaki,et al.  Identification of a novel gene, LDOC1, down-regulated in cancer cell lines. , 1999, Cancer letters.

[31]  K. Rajewsky,et al.  Human Immunoglobulin (Ig)M+IgD+ Peripheral Blood B Cells Expressing the CD27 Cell Surface Antigen Carry Somatically Mutated Variable Region Genes: CD27 as a General Marker for Somatically Mutated (Memory) B Cells , 1998, The Journal of experimental medicine.

[32]  L. Rassenti,et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.

[33]  F. Mancini,et al.  p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. , 1998, Blood.

[34]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[35]  S. Knuutila,et al.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.

[36]  M. Kozak.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. , 1987, Nucleic acids research.

[37]  ONSTANZE,et al.  GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .

[38]  G Leone,et al.  The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease , 2007, Leukemia.

[39]  L. Medeiros,et al.  TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. , 2006, Methods in molecular biology.

[40]  Kevin R Coombes,et al.  Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. , 2005, BioTechniques.

[41]  L. Bullinger,et al.  Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.

[42]  Peter Lichter,et al.  Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis , 1999, Journal of Molecular Medicine.

[43]  F. Mancini,et al.  p 53 Expression in B-Cell Chronic Lymphocytic Leukemia : A Marker of Disease Progression and Poor Prognosis , 1998 .